window.pageData = {"stock":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合A","fundSecondLevel":"hybrid","fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50410000","tickerId":50410000,"name":"东吴基金管理有限公司"},"managers":[{"name":"毛可君","stockType":"fund_manager","stockCode":"db20802586","exchange":"fm","tickerId":131110219190}],"hotMetrics":{"fss":{"stockId":3000000002919,"type":"fss","f_s_s_d":"2024-06-29T16:00:00.000Z","f_ins_h_s_r":0.0078000000000000005,"f_ins_h_s_r_c_hy":0.005900000000000001,"f_ins_h_s_r_c_1y":0.0077,"f_ind_h_s_r":0.9922,"f_ind_h_s_r_c_hy":-0.005900000000000016,"f_ind_h_s_r_c_1y":-0.007699999999999929,"f_h_a":9841,"f_h_s_a":9830,"last_data_date":"2025-12-30T16:00:00.000Z"},"fpr":{"stockId":3000000002919,"type":"fpr","f_p_r_fys_ssc":8947,"f_p_r_fys_ssrp":0.4040912139503689,"f_p_r_m1_ssc":9348,"f_p_r_m1_ssrp":0.07125280838771798,"f_p_r_m3_ssc":9171,"f_p_r_m3_ssrp":0.5845147219193021,"f_p_r_m6_ssc":8947,"f_p_r_m6_ssrp":0.43281913704448916,"f_p_r_y1_ssc":8429,"f_p_r_y1_ssrp":0.9496915045087803,"f_p_r_y2_ssc":7799,"f_p_r_y2_ssrp":0.6491408053347012,"f_p_r_y3_ssc":7013,"f_p_r_y3_ssrp":0.9185681688533942,"f_p_r_y5_ssc":4535,"f_p_r_y5_ssrp":0.9618438464931628,"f_cagr_p_r_fs_ssc":9328,"f_cagr_p_r_fs_ssrp":0.8501125763911226},"fp":{"stockId":3000000002919,"type":"fp","f_p_r_fys":0.09222628197051597,"f_p_r_m1":0.14699655993649086,"f_p_r_m3":0.023736419461500624,"f_p_r_m6":0.04634882317440958,"f_p_r_y1":-0.08429280659131821,"f_p_r_y3":-0.08448621818565838,"f_p_r_y5":-0.4502504914706065,"f_cagr_p_r_fs":-0.014319873508191083,"f_p_r_d1":0.0015879317189360087,"f_p_r_y2":0.22391641959621555,"last_data_date":"2026-07-05T16:00:00.000Z","f_i_d":"2016-08-10T16:00:00.000Z"},"ff":{"stockId":3000000002919,"type":"ff","f_m_f":1198521,"f_m_f_r":0.012,"f_c_f":199753,"f_c_f_r":0.002,"f_m_a_c_f":1398274,"f_m_a_c_f_r":0.014,"f_m_c_f_d":"2024-06-29T16:00:00.000Z","f_c_fr":0.002,"f_fr_d":"2025-12-30T16:00:00.000Z","f_m_fr":0.012,"f_mac_fr":0.014},"f_nlacan":{"stockId":3000000002919,"type":"f_nlacan","f_nv_d":"2026-07-05T16:00:00.000Z","f_nv":0.8669,"f_nv_cr":-0.017565729827742405},"f_as":{"stockId":3000000002919,"type":"f_as","f_tas":69882042.4403,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000011948,"name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","fundStatus":"normal","stockCode":"011948","tickerId":11948,"shortName":"东吴智慧医疗量化混合C","__csrcFundId":630,"lastUpdated":"2025-01-04T00:32:09.699Z","inceptionDate":"2021-04-13T16:00:00.000Z","exchange":"jj","followedNum":6,"fundCollectionId":4000050410000,"currency":"CNY","status":"normal","masterFundFlag":null,"activeFundFlag":null,"classificationFlag":null,"closedEnd":null,"etfFundFlag":null,"feederFundFlag":null,"indexFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"pinyin":"dwzhyllhcllhpzhhxzqtzjj"}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000002919,"stockId":688235,"holdings":51683,"marketCap":12072631,"netValueRatio":0.0964,"quarterlyChange":-0.1303425167535377,"stock":{"stockCode":"688235","tickerId":688235,"exchange":"sh","stockType":"company","name":"百济神州"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000002919,"stockId":603127,"holdings":322500,"marketCap":11029500,"netValueRatio":0.0881,"quarterlyChange":-0.023136246786632175,"stock":{"stockCode":"603127","exchange":"sh","stockType":"company","tickerId":603127,"name":"昭衍新药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000002919,"stockId":600276,"holdings":198900,"marketCap":10983258,"netValueRatio":0.0877,"quarterlyChange":-0.07302333389289883,"stock":{"stockCode":"600276","exchange":"sh","stockType":"company","tickerId":600276,"name":"恒瑞医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000002919,"stockId":603259,"holdings":105500,"marketCap":10349550,"netValueRatio":0.0826,"quarterlyChange":0.08230361871138547,"stock":{"stockCode":"603259","exchange":"sh","stockType":"company","tickerId":603259,"name":"药明康德"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000002919,"stockId":688506,"holdings":36748,"marketCap":10215944,"netValueRatio":0.0816,"quarterlyChange":-0.13958526771897228,"stock":{"name":"百利天恒","exchange":"sh","stockType":"company","stockCode":"688506","tickerId":688506}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000002919,"stockId":688331,"holdings":64100,"marketCap":8254157,"netValueRatio":0.0659,"quarterlyChange":0.6553541586322154,"stock":{"name":"荣昌生物","exchange":"sh","stockType":"company","stockCode":"688331","tickerId":688331}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000002919,"stockId":688180,"holdings":219200,"marketCap":7634736,"netValueRatio":0.061,"quarterlyChange":0.01961358313817363,"stock":{"stockCode":"688180","tickerId":688180,"exchange":"sh","stockType":"company","name":"君实生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000002919,"stockId":300765,"holdings":238600,"marketCap":7577936,"netValueRatio":0.0605,"quarterlyChange":-0.11948988078735767,"stock":{"stockCode":"300765","exchange":"sz","stockType":"company","tickerId":300765,"name":"石药创新"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000002919,"stockId":2294,"holdings":110000,"marketCap":6744100,"netValueRatio":0.0538,"quarterlyChange":0.23733602421796118,"stock":{"stockCode":"002294","exchange":"sz","stockType":"company","tickerId":2294,"name":"信立泰"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000002919,"stockId":688428,"holdings":230340,"marketCap":6223786,"netValueRatio":0.0497,"quarterlyChange":0.31676413255360547,"stock":{"name":"诺诚健华","exchange":"sh","stockType":"company","stockCode":"688428","tickerId":688428}}],"lastFsMetrics":{"latestTurnoverRate":23.60733931438224,"latestTurnoverRateDate":"2025-12-30T16:00:00.000Z"}},"list":[{"_id":"69e8ea671398d79843fe86ff","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","stockId":3000000002919,"sao":"一季度，地缘冲突引发全球资本市场震荡，A 股市场先扬后抑、整体收跌；创新药年初反弹上行后与医药板块随市场同步调整，直至 3 月下旬由创新药率先引领板块实现强势反弹，进一步印证了创新药在医药行业的主线地位和产业韧性。产业趋势方面，创新药继续延续高景气。根据国家药监局数据，2025 年中国药企 license out 交易总金额突破1300亿美元，中国创新药产业站上发展新周期起点，2026年前三个月，我国创新药对外授权交易总额超过600亿美元，接近2025年全年的一半，我国创新药继续取得新突破，保持良好发展势头。立足当下，中国创新药产业核心竞争力已获得全球跨国药企MNC广泛认可；展望未来，行业有望逐步孕育出具备全球影响力的制药领军企业。依托更快更好更经济的核心产业优势，创新药产业趋势有望长期向好，我们在一季度继续创新药主线配置。","lastUpdated":"2026-04-22T15:33:59.534Z","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2026年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1478143","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69cc256b1dc8b83221c66487","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-03-30T16:00:00.000Z","stockId":3000000002919,"sao":"2025年，申万医药行业指数录得11.94%涨幅，恒生医疗保健录得56.95%涨幅，一举终结了2021年以来的年线四连跌（数据来源：Wind）。医药行业整体回暖主要是由创新药产业趋势驱动，尤其是前三季度伴随着数起超预期的大型BD授权交易，创新药板块整体开启了系统性价值重估行情，快速上涨，然后自7-8月开始进入调整阶段。根据药监局数据，2025 年中国药企 license out 交易总金额突破1300亿美元，中国创新药产业站上发展新周期起点；中国创新药在研管线从数量规模与研发推进进度双维度考量已跻身全球第二，成为仅次于美国的全球优质创新药管线核心高地。立足当下，中国创新药产业核心竞争力已获得全球跨国药企MNC广泛认可；展望未来，行业有望逐步孕育出具备全球影响力的制药领军企业。我们继续关注创新药主线，较为看好我国创新药中长期产业趋势。","lastUpdated":"2026-03-31T19:50:03.037Z","mo":"宏观经济层面，2025年上半年我国经济韧性较强，下半年经济边际走弱。结构看，2025年供给明显强于需求，外需整体强于内需，内需不足的问题仍然凸显。 展望2026年，预计出口韧性有望仍强；政策有望继续加码、内需温和修复；GDP增速或前高后低，全年GDP目标可能在4.5%-5%之间。宏观政策方面，政策基调或将延续偏积极、偏扩张，推动“内需主导、消费拉动、内生增长”。财政方面，2026年预计或也仍然偏积极、偏扩张。货币方面，2026年宽松有望还是大方向。因此，我们认为展望证券市场2026年仍然值得积极期待和积极关注。 具体到医药行业层面，展望 2026 年，创新药产业趋势有望持续，创新药及其产业链或继续成为医药板块核心关注主线之一，AI医疗有望在商业模式上更进一步发展，其他医药细分领域伴随着时间累积有望在经营层面筑底向好，因此，医药行业整体我们保持积极关注。2025 年创新药板块系统性价值重估，呈现高贝塔属性，2026 年创新药行业或转向聚焦阿尔法，创新药投资逻辑随之回归临床价值本质——临床试验推进与临床数据读出的驱动效力，相较 BD 合作的驱动，或许将更为坚实可靠。依托更快更好更经济的核心产业优势，创新药产业趋势或长期向好，出海逻辑或长存。与此同时，创新药产业链核心配套的 CXO 行业亦有望充分受益于产业发展红利，行业订单与经营业绩的持续修复改善值得期待。","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1457710","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603fb","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-27T16:00:00.000Z","stockId":3000000002919,"sao":"三季度，市场以AI为代表的科技表现相对突出，医药整体震荡。其中，创新药由于短期缺乏催化、被科技板块虹吸资金、国际地缘政治等原因呈现调整态势，医疗器械等相对低位板块在医药内部轮动中呈现避险防御特征。我们认为应该持续关注产业趋势作为核心线索，我国创新药产业低成本高效率的全球竞争优势较为显著，在多年累积与发展后的创新能力和技术竞争力有望持续发挥并引领产业走向正循环。中国创新药或才刚刚开始真正参与欧美医药市场的商业价值分配，未来产业逻辑与业绩兑现的时间与空间可能都较为充足。报告期内我们继续以产业趋势和公司竞争力为基础构建了创新药为主的组合配置。展望后市，我们比较持续看好我国创新药为代表的中长期医药产业发展趋势。","lastUpdated":"2026-03-09T13:10:54.173Z","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2025年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1375879","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603fa","date":"2025-06-29T16:00:00.000Z","stockId":3000000002919,"sao":"今年上半年，市场整体震荡上行，4月初因国际贸易形势造成短期较大波动，但随后市场在较快时间内就展开了持续修复态势。其中，医药行业整体向好，创新药表现突出，成为引领板块的市场主线。尤其是4月初的短期扰动后创新药是几乎最快回升向上的板块之一，市场的快速纠正体现了对创新药产业趋势的认可与信心。国内药企和海外跨国大药企MNC的大额BD交易事件频频落地与未来的交易常态化预期，实质上集中反映了我国创新药产业在多年累积与发展后的创新能力和技术竞争力，我国低成本高效率的创新药资产有望未来得以持续重估。本轮创新药行情是由明确的产业趋势驱动，中国创新药才刚刚开始真正参与欧美医药市场的商业价值分配，未来产业逻辑与业绩兑现的时间与空间可能都相对较为充足。报告期内我们继续以产业趋势和公司竞争力为基础构建了创新药为主的组合配置。展望后市，中长期我们比较看好我国创新药为代表的医药产业发展趋势。","declarationDate":"2025-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.170Z","mo":"宏观经济层面，2025年上半年我国经济整体韧性较强。其中二季度宏观经济波动加大，主因是4月中美关税升级、地产走弱和消费下行。随着中美谈判取得实质性进展、高关税缓和，带动经济触底反弹，二季度GDP增速仍有韧性。展望2025年下半年，关税不确定性或仍在，内需不足的问题仍待解决。　　展望下半年，我们对下半年A股市场行情相对比较乐观，认为市场结构性机会可能比较多。我们认为当前A股市场可能处在历史相对三重底：估值底、政策底和业绩底，中长期有望具备较显著投资价值。此外，在低利率环境下，A股市场对机构资金、个人投资者及海外资本的吸引力有望进一步增强，市场流动性可能会比较充裕。具体行业方面，我们中长期相对比较看好创新药产业趋势的持续性与成长空间。","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2025年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1342802","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603f9","date":"2025-03-30T16:00:00.000Z","stockId":3000000002919,"sao":"一季度，权益市场整体表现为以科技领涨为主的结构性行情特征，港股相较A股具有较显著超额收益。根据WIND统计，上证指数、沪深300、创业板指、科创综指、恒生指数一季度涨跌幅分别为-0.48%、-1.3%、-1.77%、+6.45%、+15.25%。医药板块方面，医药生物申万行业指数、恒生医疗保健指数一季度分别上涨2.29%、25.23%。 医药板块一月表现平淡，二月以来AI医疗、创新药相继有较好表现，尤其是创新药板块在二月和三月持续表现较为突出，主要原因还是在于诸多事件加强了市场对我国创新药产业趋势的认可度。具体包括近期部分国内药企与海外MNC的BD交易频发、我国创新药企随着年报披露显示逐渐迎来盈利周期、创新药得到我国政策和医保多维度支持等方面，这些实质上是集中反映了我国创新药产业在多年的累积与发展后医药创新能力和技术竞争力得到了越来越多的显性化证明。伴随着春节前后DeepSeek引发我国科技资产价值重估的讨论，我国低成本高效率的真创新药资产也迎来了市场的广泛关注与肯定。报告期内我们以产业趋势为基础构建了创新药为主的组合配置。展望后市，短期来看，国际贸易博弈对市场或有较大冲击，避险情绪或阶段性主导，但中长期看我们依然相对看好我国创新药为代表的的医药产业发展趋势。","declarationDate":"2025-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.167Z","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2025年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1272187","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603f8","date":"2024-12-30T16:00:00.000Z","stockId":3000000002919,"sao":"2024年，医药板块表现较差，在各申万一级行业指数中排名居末，主要原因仍在于医药国内市场支付端压力的担忧，同时医药出海市场也受地缘政治冲突等扰动。但实际上我们可以看到国内医药政策环境与医药出海环境实际上都呈现边际改善迹象，有望助力医药板块筑底。生物医药行业作为新质生产力代表之一，报告期内我们仍以成长板块为主要配置，从产业趋势出发，中长期比较关注医药以科技创新为主线的成长机会，坚持自下而上选股并集中关注创新药、创新器械以及各细分领域内成长空间有望较足的优质医药公司。","declarationDate":"2025-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.164Z","mo":"2024年我国GDP同比增长5%，整体符合年初预期，证券市场在年初开始调整后震荡，9月底开始显著回暖，主要是9月底一揽子政策集中出台提振了信心，此后政策效果逐步显现。展望2025年，政策大方向可能需要更积极、更扩张、更给力。具体看，重点关注4个方面： 一是货币宽松有望仍是方向，预计降准、降息仍然可以期待。二是财政可能进一步加码，按照测算，2025年广义赤字率相比2024年可能明显抬升，财政支出节奏也有望前置。三是产业政策预计也可能进一步发力，包括更大规模的“以旧换新”、存量商品房收储、北京和上海可能进一步放松地产限购限售。四是着力构建现代产业体系和发展新质生产力尤其是跟AI人工智能相关的战略产业和新兴产业。我们判断，当前A股市场具有以下三大特征：（1）市场估值处在历史相对底部区域；（2）政策宽松拐点相对明确；（3）2025年A股上市公司净利润增速有望进入上行趋势。另外，2025年随着海外资金对中国企业竞争优势的认识，中国资产有望得到重估。其中，医药生物行业2024年在申万行业指数中表现靠后，连续四年收跌，展望2025年，有望在基本面、政策面、估值面、筹码面等多方面出清，未来向上可期。","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2024年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1254261","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603f7","date":"2024-06-29T16:00:00.000Z","stockId":3000000002919,"sao":"上半年市场整体承压，个股表现相对弱于指数，市场风格分化比较明显。其中，根据Wind统计，医药生物申万行业指数上半年累计跌幅达到21%，当前已非常接近2024年2月5日指数位置。 政策面上，我们看到各地陆续出台创新药支持政策，国务院发布大规模设备更新行动方案并陆续在各地开始逐步落地，这些积极政策都对市场有所提振，同时医药反腐的持续推进和各地药品比价小程序的上线又令一部分投资者情绪谨慎起来。基本面上，医药上半年业绩存在高基数压力，下半年医药业绩有望在低基数下好转。报告期内我们聚焦布局于高成长的创新药械和稳健增长的中药OTC等领域机会。长期来看，医药之中的优质创新成长资产和稳健ROE资产有望穿越周期。","declarationDate":"2024-07-18T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.161Z","mo":"2024上半年我国经济延续修复，但有一定下行压力。出口、工业生产、制造业投资链条是经济的主要支撑，而地产、基建实物工作量和消费等内需相关方向压力依然较大。展望2024下半年，GDP增速有望维持在较高水平，但可能需要稳增长、稳地产、稳消费的政策进一步发力。结构上看，2024下半年经济的主要支撑可能仍在出口和出口链，预计年内出口有望仍有韧性。与之对应地，工业生产、制造业投资预计也有望保持较高增速，同样是经济的重要支撑。但是，内需相关的社零、地产、基建实物工作量仍然可能面临诸多约束。宏观政策层面，鉴于当前经济仍有一定压力，后续更多稳增长、稳需求、稳地产相关政策有望陆续出台，但强刺激政策的可能性或不高。促改革有望也是重点方向。7月二十届三中全会召开，提出了300多项具体改革任务，亮点包括：高水平社会主义市场经济、教育科技人才一体化、新质生产力、财税体制改革、统一大市场、土地改革、国企民企关系等，大体确定了未来5-10年中国经济发展路线。展望2024年下半年A股市场，我们认为当前A股市场可能处在历史相对底部区域，中长期投资价值有望比较明显。我们对2024年下半年A股市场行情相对比较乐观，认为可能存在结构性投资机会。","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2024年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1147137","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603f6","date":"2024-03-30T16:00:00.000Z","stockId":3000000002919,"sao":"一季度，市场呈深V走势，春节后持续回暖向上。其中，医药生物申万行业指数在申万一级行业中表现靠后，但以创新为代表的的结构性增量机会仍然相对较为显著并有望持续。医药基本面有望持续出清。尽管高基数叠加行业反腐影响，医药2024年一季度整体增速相对不快，但全年有望前低后高。医药政策端也有望持续回暖。2024政府工作报告中提到，加快前沿创新药等产业发展。创新药作为新质生产力代表，也是全球具备竞争力的战略性新兴产业，未来我们或有望看到国内政策对创新药发展的系统性全方位支持。我国创新药企在ADC、双抗、细胞治疗等全球前沿新方向均展现出较强竞争优势，在减重、阿尔茨海默症、NASH等空间广阔的领域均有积极布局，我国创新药产业有望百花齐放。叠加考虑全球降息周期，尽管中途可能难免震荡但2024年创新有望引领医药板块积极向上。总体而言，医药行业目前或处于政策面、基本面、估值面、交易面的多重相对底部，以创新药为代表的的新兴产业发展趋势有望积极向上，因此展望后市乐观。报告期内我们布局侧重于创新药产业。","declarationDate":"2024-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.158Z","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2024年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1073832","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603f5","date":"2023-12-30T16:00:00.000Z","stockId":3000000002919,"sao":"回顾2023年，医药生物申万行业指数连续第三年收跌，我们的组合回撤较大，表现很不理想。年初我们预期的放开后复苏逻辑并没有兑现，医药行业整体缺乏主线行情的情况下高度博弈、主题盛行的结构特征显著，子行业快速轮动。未来我们会更加谨慎审视持仓，争取净值的修复与增长。当前市场整体处于相对底部区域，复盘历史似乎每次看不见希望的阶段往往都可能是蕴含较好长期投资回报机会的起点阶段。我们将继续致力于挖掘并跟踪医药行业中产业景气并具备竞争优势的企业，在对市场保持谨慎乐观的基础上构建组合，守望市场回暖。具体方向上，我们持续关注创新药械的投资机会，我们判断这有望是医药里产业趋势向上的成长性资产，创新药和创新器械具有渗透率低、定价能力强、患者真正获益的属性，并且有望受益于美国降息周期。此外，我们也关注中药、疫苗等领域长期受益于银发经济可能带来的增量需求机会。","declarationDate":"2024-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.156Z","mo":"展望2024年，我们判断，国内经济在政策可能持续发力的基础上可能温和复苏。鉴于2024年国内经济仍可能有下行压力，宏观政策大概率继续偏宽松，国内有望“中央加杠杆”，中美货币政策可能从分化逐步走向一致。海外方面，2020年3月以来美联储持续加息，联邦基金目标利率从2020年3月的0.25%加至2023年7月的5.5%，加息幅度达到525bp。2023年继续加息，幅度达到100bp，对国内货币政策和资本流动有一定掣肘。整体看，2024年美国通胀中枢可能趋于回落，美联储大概率从加息转为降息，中美货币政策可能从过去3年的分化逐步走向一致，国内货币政策面临的制约也可能有所弱化。2024开年首月，市场大幅调整，成长板块领跌，其中，根据WIND统计，医药生物申万行业指数单月跌幅超过18%，位居自2000年以来历史单月跌幅前五，仅次于2016年初熔断和2008年全球金融危机阶段的表现。沪深300指数从2021年2月18日见顶回落至今最大调整幅度在47%左右，医药生物申万行业指数也从2021年2月18日见顶回落至今最大调整幅度超过52%，调整时间接近3年，估值基本到了历史相对低分位数，并且2024年A股上市公司利润增速有望进入上行周期。我们认为，当前A股市场中长期投资价值可能相对比较明显，或值得投资者关注。美国国债收益率大幅下行，今年美国预期可能进入降息周期，基准利率的大幅下行有望有利于创新药的融资，我们相对看好国内的创新药的未来发展。","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2023年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1055005","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603f4","date":"2023-09-29T16:00:00.000Z","stockId":3000000002919,"sao":"三季度，医药行业整顿事件影响较大，尽管短期会对相关医药公司业绩造成一定影响，但预计长期来看对医药行业影响有望更为积极正面。长期来看，反腐有望强化企业的产品力、加速行业出清，产品、经营、管理等方面具有突出竞争优势的创新药械有望实现可持续的优质成长。医药行业目前处于基本面、估值面、交易面的多重相对底部，基于行业需求稳定性、政策引导方向、估值性价比，报告期内本基金布局侧重于创新药械、医疗服务、CXO等领域。","declarationDate":"2023-10-24T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.153Z","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2023年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=990468","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603f3","date":"2023-06-29T16:00:00.000Z","stockId":3000000002919,"sao":"上半年医药表现疲弱，存量博弈市场导致内部结构分化显著。医药生物申万行业指数上半年累计涨跌幅为-5.6%，同期万得全A（除金融石油石化）累计涨跌幅为3.3%，医药显著跑输。从申万二级子行业来看分化极致，其中中药（上涨9.1%）领涨，生物制品（下跌-12.9%）和医疗服务（下跌21.6%）大幅回调。年初市场交易复苏，强预期弱现实下交易线索转为持续集中于科技创新与“中特估“主题，博弈政策也逐渐成为当下重要线索。医药当前处于多重相对底部，基于行业刚性增长需求和复苏态势、政策引导方向、估值性价比，报告期内本基金布局侧重于内需，包括中药、创新药、医疗服务等领域。本基金持续关注医药行业多个持续深度回调板块是否具备潜在的反转机会。此外前期强势板块比如符合政策引导方向的中药行业，本基金重点关注公司是否有望由政策驱动转向政策加业绩驱动进而提升长期成长性。","declarationDate":"2023-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.150Z","mo":"宏观经济层面，2023年上半年经济复苏低于市场预期，市场对经济基本面和政策面预期较为悲观。展望2023年下半年，预计中国经济虽可能有压力但大概率温和触底，有希望进入弱复苏阶段。政策层面，2023年国内通胀压力可能相对较小，而海外通胀也已呈现下行趋势，下半年国内外货币政策有望由分歧逐渐走向一致，全球流动性可能由紧变松。2023年下半年，预计国内可能继续保持中性偏宽松的货币政策格局，以美联储为代表的发达国家央行有望结束加息周期。资本市场方面， 2023年下半年市场向上机会可能大于向下风险。展望2023年下半年，A股基本面、流动性和估值这三大因素中至少有两个因素是有望改善的。一是国内经济基本面有望触底。二是海外美联储有望在2023年结束加息，国内流动性继续维持中性偏宽。三是当前A股估值处于历史相对偏低水平。这对权益市场来说或许是个相对有利的组合。医药行业，从需求端看市场空间仍然有望较大，从供给端看中国拥有全球庞大的工程师红利，从支付端看医保政策趋于边际缓和并鼓励创新，医药仍有望是具备持续诞生优质公司土壤的长期优质赛道。","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2023年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=964385","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603f2","date":"2023-03-30T16:00:00.000Z","stockId":3000000002919,"sao":"23年一季度市场整体表现为较为显著的结构性行情。年初以来在国内基本面持续复苏预期的支撑下，A股1月整体快速上行，市场主要交易复苏预期；随着外围扰动加剧以及国内复苏力度与持续性待验证，市场自1月底以来行情明显分化，科技板块和“中特估”领涨，政策、主题等因素的催化成为重要交易线索。医药板块一季度内部表现分化极致，政策和国企改革催化下，中药持续强势，医疗服务、创新药、CXO、器械等医药大多数细分板块则普遍经历了过山车行情甚至连续回调至阶段性新低。考虑到未来国内复苏仍有望好于预期，美联储有望年内结束加息，投融资数据有望环比改善，医药主赛道有望迎来上行。医药极致结构性行情下，本基金一季度净值表现跑输基准。","declarationDate":"2023-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.148Z","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2023年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=883734","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603f1","date":"2022-12-30T16:00:00.000Z","stockId":3000000002919,"sao":"2022年市场受到较大内外部冲击影响，行情一波三折，各大指数均有较大幅度下跌，根据wind统计，上证指数下跌15.1%，沪深300、深证成指下跌超21%，代表成长的创业板下跌29.3%、科创50下跌31.3%。医药生物申万指数全年下跌超过20%，在31个申万一级行业指数中表现位列后三分之一，既有海外加息冲击以及医药投融资周期的影响，也有国内政策影响和企业盈利受大环境压制的因素。前三季度由于上述压制因素，医药行业整体表现尤其疲弱，根据wind统计，医药生物申万指数累积下跌幅度近28%，位居31个申万一级行业指数的倒数第5，此后伴随着防控措施优化的预期与实际推出，医药行业四季度跟随整体市场上行而回暖。四季度，医药各细分板块几乎均有轮动机会但也经历了过山车般的波动与博弈。由于医药全年结构性机会重点围绕某大环境影响因素展开、以及存量市场下医药各细分板块不断超跌反弹轮动等因素，因此医药板块行情呈现快速轮动与高度博弈的极致结构特征。展望2023年，市场的核心关键词之一可能是复苏，把握内需复苏的相对确定性机会或尤为重要。医疗场景常态化的修复，导致医药行业既可能存在刚需必选复苏机会，也可能具备可选升级消费需求复苏机会，这些都有望给医药带来业绩比较优势。此外及其值得重视的是，2023年医药政策的预期稳定性相较前两年也显著提高。相对低估值低配置的医药板块在具备业绩比较优势的情况下，有望迎来表现更为乐观的2023年。基于四季度的政策变化与环境演绎，以及对2023年的机会展望，本基金报告期内重点配置了医疗服务、CXO、零售药店与创新器械。本基金长期关注医药消费、医药创新、医疗服务的成长机会。","declarationDate":"2023-01-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.145Z","mo":"宏观经济层面，2023年中国经济有望迎来一轮复苏。国内经济自2021年下半年呈现减速迹象，并在2022年遭受大环境冲击，国内GDP增速从2022年一季度的4.8%降至2022年四季度的2.9%。展望2023年，国内经济有望触底并适度修复，市场的核心关键线索可能为“复苏”，复苏的高度仍需进一步跟踪研判。政策层面，2022年国内和海外呈现比较明显的分化，2023年国内外货币政策可能将由分歧逐渐走向一致。国内货币政策在2022年整体偏宽松，全年实施了两次降准，1年期LPR利率从3.8%降至3.65%，5年期LPR利率从4.65%降至4.3%。展望2023年，国内通胀压力可能相对较小，而海外通胀也已呈现明显的下行趋势，预计2023年国内大概率继续保持中性偏宽松的货币政策格局，以美联储为代表的发达国家央行则有望结束加息周期。资本市场方面，我们认为2023年市场可能明显优于2022年，市场向上机会有望大于向下风险。2023年的A股有望迎来基本面和流动性的双轮驱动。一是国内经济环比修复，企业盈利逐级修复。二是海外美联储有望在上半年结束加息，国内流动性继续维持中性偏宽，这对权益市场来说可能是个相对有利的组合。长期看好医药、消费、高端制造的成长机会，从需求端看这些领域市场空间较大，从供给端看中国拥有全球庞大的工程师红利，参考海外经验，这些领域中有望诞生优秀公司。","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2022年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=871811","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603f0","date":"2022-09-29T16:00:00.000Z","stockId":3000000002919,"sao":"2022年三季度，医药行业仍然持续调整，盖因市场和行业层面多重制约。宏观与流动性方面，美国通胀数据超预期，市场提升了美联储加息幅度的预期，俄乌战争持续胶着，同时国内经济仍存稳增长压力。具体产业方面，美欧与中国摩擦边际加剧对清洁能源、医药制造等成长板块造成风险偏好与基本面预期的双重冲击，拜登政府签署行政命令扶持本土生物技术和生物制造，严重影响了医药外包产业链情绪。尽管医药整体持续调整，板块在三季度的表现还是可以窥见一些曙光。我们陆续看到政策面和基本面均有边际利好趋势——新基建在持续拉动医药投资建设、贴息贷款有望释放设备采购需求、脊柱集采结果令市场对于骨科集采乃至高耗集采部分转向乐观、种植牙医疗服务费落地价格远好于预期等等，这些都引起了医药较为显著的结构性行情。可见行业处于相对极致的悲观底部之时任何边际向上的微小变化可能都足以引发星火燎原之势。医药历经一年多的持续深度调整，除医药基金以外的机构医药持仓几乎已降至相对历史冰点。尽管医保控费和中美脱钩的预期仍将可能对板块有影响，但考虑到医药处于政策预期底、持仓底、估值底的多重相对底部，我们可以更细致的甄选细分领域与个股，有望有机会以较好价格布局中长线投资。报告期内，本基金的布局相对均衡，注重公司的估值性价比与安全边际，重点配置了医疗服务、消费医疗和中药品牌消费品、医疗设备、零售药房等医药细分领域。本基金将致力积极跟踪产业发展前沿趋势，集中关注医药行业的高成长方向，力争收获相对于医药行业的长期超额收益。","declarationDate":"2022-10-25T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.142Z","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2022年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=806111","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603ef","date":"2022-06-29T16:00:00.000Z","stockId":3000000002919,"sao":"2022年上半年，市场开年即持续深度调整，4月底开始企稳筑底强势反弹，在外围金融市场普遍回调的情况下走出了相对独立行情，医药行业整体表现位于申万31个一级行业中的后三分之一。回顾上半年的反弹，截至2022/06/30，5月以来上证指数、深证成指、创业板指分别上涨11.54%、17.01%、21.19%，医药生物（申万）行业指数同期上涨11.74%。医药行业在5月以来持续回暖的市场中表现相对弱势，但我们对医药未来修复的持续性和空间表示乐观，乐观的背后是医药行业成长属性的支撑。短期来看，疫情扰动过后，医药经营运行有望在持续修复大方向之中。同时资本市场上医药行业指数反弹幅度相对不大，因此对应的是对于医药行业下行空间理应具备一定的信心。展望未来，我们坚定相信医药中长期有望持续呈现向上发展趋势，创新和科技始终是产业进步向前的核心驱动力。医药整体在从去年开始的长时间调整中也较为充分的消化了估值与持仓的问题。此外，国内医保控费政策预期基本趋于稳定，全球流动性收紧、海外医药资本周期等对医药产业链影响的预期也已在股价层面定价较为充分。经历了市场对医药政策、医药估值、医药投融资环境等各方面因素的极致担忧后，医药行业基本面、政策面、估值面都有望酝酿着中长期筑底回升的潜力。本基金在报告期重点配置了医疗服务、创新药产业链、生命科学服务上游、医疗设备、消费医疗和品牌消费品等长期看好的医药细分领域。本基金将积极跟踪产业发展前沿趋势，集中布局医药行业的高成长方向，力争收获相对于医药行业的长期稳健超额收益。","declarationDate":"2022-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.140Z","mo":"宏观经济层面，2022年下半年中国经济有望确定性环比回升。国内经济自2021年下半年呈现减速迹象，并在2022年上半年遭受本土奥密克戎疫情黑天鹅冲击，国内GDP增速从2022年一季度的4.8%降至二季度的0.4%。在国内稳增长政策发力和海外出口超预期的驱动下，国内经济有望稳步走出二季度的疫情冲击，下半年国内经济相比二季度有望环比逐渐改善，但整体呈现弱复苏的概率较大。政策层面，2022年上半年国内和海外呈现比较明显的分化，预计下半年依然是国内宽海外紧的货币政策格局。医药行业方面，经过较长时间、较大幅度的持续调整后板块估值处于合理区间，投资机构对于医药板块的配置比例也处于近十年较低位置，战略视角上市场有望对于医药逐步重视起来。医药政策上，创新药政策环境有所边际改善。近期2022年医保目录调整方案中创新药医保谈判新增简易续约规则清晰、降幅可控，政策风险减少。近日北京医保局还发布CHS-DRG付费政策，提出满足相关条件的创新性药品、医疗器械、诊疗项目可通过申报获得除外支付。从中可以看出医保对于真正有临床价值的创新药械的鼓励和支持。新药新技术的创新动力是医药真正的成长驱动力，政策鼓励创新之下，医药有望在经过较长时间、较大幅度调整后政策、估值、持仓齐筑底，迎来回暖机遇。","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2022年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=785464","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603ee","date":"2022-03-30T16:00:00.000Z","stockId":3000000002919,"sao":"开年以来市场整体疲弱，A股、港股、中概股都深度调整。医药板块变现也不尽如人意，主要原因首先是市场因素，美联储加息、俄乌冲突、中美关系等风险使得投资者对市场前景趋于悲观；其次，医保政策端压力、一级市场悲观预期等持续压制医药板块估值。3月16日国务院金融稳定发展委员会召开专题会议，研究当前经济形势和资本市场问题，直指目前的很多痛点，这化解了市场短期的一些焦虑，市场有望筑底企稳。国际形势和国内疫情增加了各行业业绩的不确定性，此时医药的当期业绩确定性优势将有望在疫情大环境情况下凸显，同时考虑到随着医疗的回调，原本估值偏高和持仓拥挤问题可能得到较为充分消化，因此综合来看，政策面、基本面、估值面均有望酝酿着医药中长期筑底回升的潜力。本基金报告期内在配置上有所均衡，配置方向上继续挖掘景气度具备相对优势的产业方向，综合考虑估值性价比与公司高质量成长性的平衡。中长期看，考虑到终端需求的刚性和升级属性，考虑到创新驱动的供给端持续迭代升级，医药行业仍然有望是值得长期投资的优质成长赛道。本基金重点关注不受限于政策的高成长医药行业，包括但不限于产业链上游的创新产业链CXO板块、生命科学服务板块等，以及品牌消费健康领域，也重点关注通过创新迭代在医保控费大趋势下呈现持续成长能力的优质药械企业。","declarationDate":"2022-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.137Z","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2022年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=727185","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603ed","date":"2021-12-30T16:00:00.000Z","stockId":3000000002919,"sao":"2021年，医药行业表现为显著的内部行业轮动特征，结构分化显著。长时间持续的极致边际景气定价风格后，此前较为强势的高景气赛道历经政策担忧与景气周期论证，波动加大，业绩与估值再平衡。本基金报告期内基于行业风格轮动在配置上有所均衡，配置方向上将努力继续挖掘景气度相对优势的医药产业方向，综合考虑估值性价比与公司高质量成长性的平衡。","declarationDate":"2022-01-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.134Z","mo":"人口结构的老龄化和城镇化驱动医药需求的长期景气。同时，受医保支付约束，行业内分化可能也会加大。中长期看，考虑到终端需求的刚性和升级属性，考虑到创新驱动的供给端持续迭代升级，医药行业仍然有望是值得长期关注的优质成长赛道。本基金重点关注不受限于政策的高成长医药行业，包括但不限于产业链上游的生命科学服务、创新产业链CXO、制药设备制造等，也重点关注通过创新迭代在医保控费大趋势下呈现持续成长趋势的优质药械企业。","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2021年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=714139","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603ec","date":"2021-09-29T16:00:00.000Z","stockId":3000000002919,"sao":"2021年中国经济在后疫情时代经历了上半年的温和修复后，在三季度经济开始减速。中国货币政策宽松超预期，四季度国内流动性有望优于海外流动性。基于自上而下的宏观经济政策和自下而上的行业景气度，就2021年四季度我们判断如下：考虑到央行全面降准解除了对于后续流动性收紧的后顾之忧，叠加中美贸易关系缓和、新冠特效药进展等对风险偏好的提振，对中国权益市场维持乐观判断。但考虑到2021年下半年的国内流动性偏宽松并不是2020年全球的全面性流动性大宽松，因此四季度的A股行情可能更多的是结构性行情而非全面性行情。本基金三季度继续配置高景气的创新药产业链和医疗服务，看好CXO业绩高增长的确定性和持续性，看好医疗服务龙头强者恒强的竞争优势和量价齐升的消费升级趋势。医药行业短期可能会因为政策因素或者市场系统性风险而带来回调，但中长期看，考虑到终端需求的刚性和升级属性，考虑到创新驱动的供给端持续迭代升级，医药行业仍然是值得长期关注的优质成长赛道，每次行业调整都有望带来配置机会。本基金致力于探寻最符合医药产业发展趋势的高景气优质公司，四季度将继续基于产业趋势的深度研究，沿着高景气主线，努力持续挖掘业绩增速与估值相对匹配的公司作为重点投资对象。","declarationDate":"2021-10-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.131Z","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2021年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=649442","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603eb","date":"2021-06-29T16:00:00.000Z","stockId":3000000002919,"sao":"2021年宏观环境大概率处于“经济修复+政策先稳后紧”的组合，本基金关注高估值风险的同时致力积极挖掘长期发展趋势良好的优质成长个股，力争以高质量成长对抗估值风险。报告期内本基金继续关注高景气的创新药产业链和医疗服务，长期比较看好为创新研发提供外包服务支持的CXO公司业绩增长的发展性和持续性，长期比较看好医疗服务龙头强者恒强的竞争优势和量价齐升的消费升级趋势。医药行业发展日新月异，短期或许会因为政策担忧或者市场系统性调整而带来板块整体回调，但中长期看，医药行业始终有望存在需求强劲、业绩持续向好的高景气细分行业和发展方向，每次行业调整都可能带来配置机会。","declarationDate":"2021-07-14T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.128Z","mo":"2021年的国内宏观经济政策环境是“经济修复+政策先稳后紧”，这样的投资环境下，医药行业的发展性行业比较优势仍然较为突出。我国医药行业有望长期处于景气周期，同时，受医保支付约束，行业内分化也可能会加大，创新药产业链、医疗服务将有望持续高景气。在经历上半年系统性的估值抬升后，下半年医药板块可能需通过业绩的兑现来逐步消化估值，长期比较看好CXO和医疗服务行业，重视每一次板块调整可能带来的配置机会。","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2021年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=628632","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603ea","stockId":3000000002919,"sao":"2021年宏观环境处于“经济修复+政策先稳后紧”的组合，本基金关注高估值风险的同时积极挖掘长期发展趋势良好的优质成长个股，致力于以高质量成长对抗估值风险。报告期内主要配置高景气的创新药及创新药产业链如为创新研发提供外包服务支持的CXO公司、医疗服务和不受医保控费影响的消费属性医药公司比如生长激素、近视防控等。医药行业发展日新月异，短期可能会因为政策担忧或者市场系统性调整而带来板块整体回调，但中长期看，医药行业始终存在需求强劲、业绩持续增长的高景气细分行业和发展方向，每次行业调整都可能带来配置机会。","date":"2021-03-30T16:00:00.000Z","declarationDate":"2021-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.126Z","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2021年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=568908","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603e9","stockId":3000000002919,"sao":"2020年，经历疫情冲击后，我国经济快速恢复，全年实现国内生产总值101.6万亿元，同比增长2.3%，成为全球为数不多实现正增长的国家；在流动性宽松以及中长期资金流入加快的背景下，A股市场迎来明显上涨，全年沪深300、上证50和创业板50分别上涨27%、19%和89%。年初遭受突如其来的疫情冲击，导致经济短时间近乎停滞，A股市场经历剧烈波动，除了医药和食品等必需消费品牌外，其他行业均有明显的下跌；随着2季度国内疫情得到控制，生产生活正常化，经济明显恢复，叠加海外疫情蔓延，我们制造业优势凸显，使得出口强劲复苏，市场经历了明显的估值修复；下半年随着海外疫情改善，全球需求改善预期明朗，市场持续向上，消费、周期和成长板块均有较好的表现。尽管全年市场整体上涨，但结构分化进一步加剧，全部A股2020年中位数涨幅为2%，远低于沪深300的27%的涨幅，盈利持续性和稳定性较好的行业龙头估值提升显著，反映投资者结构向机构投资和中长期投资转变，也体现了市场对经济增长前景的担忧。本基金专注于医药领域非药投资，致力于寻找非药子行业和个股阿尔法，报告期内积极投资高景气成长CXO赛道和长期盈利模式稳定的医疗器械龙头，整体保持仓位稳定，通过个股阿尔法获得组合整体收益。","date":"2020-12-30T16:00:00.000Z","declarationDate":"2021-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.123Z","mo":"经历了新冠疫情冲击的2020年，2021年我们将迎来后疫情时代。2021年的我国宏观经济政策环境是“经济修复+政策先稳后紧”。经济向上修复的主要动力来自于出口、制造业投资和服务型消费。出口端，全球疫苗推出后疫情有望逐步修复，全球复苏将带动我国出口继续修复。投资端，由于企业盈利不断修复，叠加出口景气，制造业将从单纯的补库向扩产能演进，制造业投资有望继续加速。此外虽然房住不炒基调下地产调控频频，但房企基于回笼现金流考量仍有动力加快开工和销售，房地产投资仍有韧性。消费端，我国疫情修复后国内服务型消费也将逐步复苏。基数效应导致国内GDP同比增速高点在一季度出现后逐季回落，但全年真实的经济修复动能可能仍然持续超预期。宏观经济政策方面，预计2021年相对2020年将有所收敛。在去年末中央经济工作会议定调宏观政策“不急转弯”指引下，一季度我国货币政策仍然以稳为主，但二季度通胀预期大概率升温，叠加疫苗逐步推进，货币政策边际上存在边际调整的风险，全年社融增速逐步回落可能逐渐成为市场共识。海外市场方面，预计以美联储为代表的海外央行货币政策调整节奏整体滞后于我国；当前来看，美联储可能于2021年下半年考虑逐步缩减购债规模，并可能于2022至2023年开始加息。综合上述分析，我们判断经济复苏和盈利增长依然是A股市场2021年的主要矛盾，但需更多考虑货币政策边际收缩对于市场估值的压力。因此，我们认为权益市场可能呈现震荡格局，企业盈利增长的确定性显得尤为重要，且需防范部分行业估值过高带来的潜在风险。","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2020年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=557765","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603e8","stockId":3000000002919,"sao":"2020年3季度，全球主要国家疫情好转，陆续开始复工复产，全球经济进入复苏通道；同时疫苗研发有序推进，也助推市场对经济复苏的预期提升，相应地，受益疫情的医药板块经历了上半年的快速上涨后，3季度整体比较平淡，对比万得全A上涨8.4%，医药和医疗板块分别上涨2.4%和1.3%，涨幅靠后。长期看，随着我国人口老龄化的加速，医药行业长期处于景气周期；另一方面，受医保支付约束，行业内分化也会加大，创新药、国产医疗器械、医疗服务将持续高景气。因此，经历3季度的估值调整后，随着业绩的逐步释放，我们认为医药板块的估值重回合理区间，我们持续看好上述高景气赛道的投资机会。本基金在报告期内依然维持中性仓位，权衡子行业景气度与估值的匹配度，增加了医疗服务的仓位，相应降低了疫苗相关公司的配置，降低组合与业绩基准的偏离度。","date":"2020-09-29T16:00:00.000Z","declarationDate":"2020-10-27T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.120Z","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2020年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=490014","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec6de7fea5b3eb04603e7","stockId":3000000002919,"sao":"2020年上半年大类资产波动源自流动性宽松，疫情之下全球处于业绩减记与政策对冲的角力期，权益及商品市场的走势表明流动性宽松最终战胜了业绩减记的悲观预期。2020年初以来，由于受到新冠疫情影响，医药是二级市场表现最为亮眼的板块。从业绩上来看，2020年Q1细分子领域创新药及产业链、药店、部分特色原料药、疫情相关物资等业绩表现亮眼，与全行业的相对比较优势明显；从流动性来看，整体上半年流动性也是远超去年同期，医药多数子版块实现“戴维斯双击”，而基于一致预期数据，Q2单季大部分医药企业业绩表现良好。二季度本基金净值累计上涨22.21%，强于wind全A指数（季度上涨14.74%）。自5月以来，债券市场陷入连绵调整，理财产品、货基收益率下降，净值型理财产品大面积亏损。由于医药行业核心品种业绩的强劲性和确定性，医药的估值溢价率和机构持仓都超过了上一次的历史高位（2014年1季度），但行业比较优势仍非常明显，在该矛盾阶段缓释后，医药大概率将在三季度迎来估值切换行情。 全球疫情的爆发促使各国加快对新冠疫苗及特效药的研发，我国迅速将生物安全纳入国家安全体系，加快补齐各类短板同时大力推动关键核心技术攻关，加大重大传染病防治、重大新药、高端医疗器械、新能源、新材料等重大科技项目的实施和支持力度，生物医药行业将中长期处于景气向好的局面。本基金严格按照量化模型在股票池内进行选股并结合择时模型进行资金管理和类股轮换，选股环节加大了对个股基本面业绩确定性及市场一致预期的权重，且主线配置个股均集中于各个细分子行业龙头，通过量化手段控制净值的最大回撤，以期实现净值曲线的稳健增长。","date":"2020-06-29T16:00:00.000Z","declarationDate":"2020-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:10:54.118Z","mo":"随着我国人口老龄化的加速，医药行业长期处于景气周期；另一方面，受医保支付约束，行业内分化也会加大，创新药、国产医疗器械、医疗服务将持续高景气。在经历上半年系统性的估值抬升后，下半年医药板块需通过业绩的兑现来逐步消化估值，相对看好医疗器械、医疗服务、医疗信息化龙头表现，等待医保政策对估值的扰动带来的投资机会。","fund":{"_id":3000000002919,"stockCode":"002919","stockType":"fund","areaCode":"cn","followedNum":12,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2016-07-10T16:00:00.000Z","setUpScale":556621000,"market":"a","tickerId":2919,"custody":"中国农业银行股份有限公司","name":"东吴智慧医疗量化策略灵活配置混合型证券投资基金","shortName":"东吴智慧医疗量化混合(002919)","fundSecondLevel":"hybrid","__csrcFundId":630,"fundStatus":"normal","lastUpdated":"2026-04-30T18:41:51.739Z","masterFundFlag":1,"inceptionDate":"2016-08-10T16:00:00.000Z","fundCollectionId":4000050410000,"currency":"CNY","masterFundShortName":"东吴智慧医疗量化混合","pinyin":"dwzhyllhcllhpzhhxzqtzjj","managers":[{"stockCode":"db20802586","stockType":"fund_manager","exchange":"fm","tickerId":131110219190,"name":"毛可君"}]},"announcement":{"linkText":"东吴智慧医疗量化策略灵活配置混合型证券投资基金2020年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=452342","linkType":"PDF","source":"csrc_pdf"}}]}